PDS Life Sciences Release: PDS SEND Express™ Service Selected By Global Biopharma Company

MT. ARLINGTON, N.J.--(BUSINESS WIRE)--PDS Life Sciences, a leading global provider of software and solutions for life sciences research and development, was selected to be the preferred provider of research data transformation services for a top-tier global biopharma company. This partnership, which was selected after a competitive evaluation process, will enable the client to effortlessly comply with the newly mandated FDA Standard for Exchange of Nonclinical Data (SEND) requirements without investment in staff or software infrastructure.

“Pharma companies, biotechs and CROs are dangerously behind in their SEND compliance preparation. We commend the management team of our client for being proactive in navigating this regulatory submission pitfall”

The services will be executed by PDS’ dedicated SEND Express™ business unit, utilizing the company’s fully secure U.S.-based data center. SEND Express is a complete outsourced service for the conversion of nonclinical studies to SEND format and includes all the components, such as the Study Data Reviewer's Guide (SDRG), needed for actual FDA submission. PDS has been responsible for more than half the trial submissions received by the FDA through April 2016.

“Pharma companies, biotechs and CROs are dangerously behind in their SEND compliance preparation. We commend the management team of our client for being proactive in navigating this regulatory submission pitfall,” said Sayed Badrawi, CEO, PDS Life Sciences.

“They have thoroughly assessed their options and selected PDS’ SEND Express team because of our unique turnkey service, high-quality scientific team and guarantee of successful submissions.”

SEND is a new FDA requirement governing the formatting of nonclinical datasets. SEND guidelines were announced in December 2014 with phased compliance going into effect starting December 2016 for certain submission types (NDA, ANDA, certain BLAs). The full set of requirements are effective beginning December 2017, including the formatting of certain IND-enabling studies. Studies started after the required dates and submitted to the FDA in a format other than SEND will not be reviewed by the FDA.

About PDS
For more than 30 years, PDS has provided intuitive software and solutions for life sciences research and development programs worldwide. Most of the world’s top 10 pharma companies rely on PDS software, as do industry-leading CROs, chemical companies, universities and regulatory agencies. The PDS software lineup is centered on Ascentos™, an integrated preclinical software data management system, which supports toxicology, clinical pathology, reproductive toxicology and anatomic pathology. PDS also offers TranSEND™, a complete FDA submission management solution, and SEND Express™, a dedicated outsourced service for FDA SEND compliant submissions, as well as powerful bioinformatics analysis and other services. Learn more at pdslifesciences.com.